


### PHARMACEUTICAL 2018



# Xenon Pharmaceuticals Inc. Rank 160 of 342





#### PHARMACEUTICAL 2018

## XENON

## Xenon Pharmaceuticals Inc. Rank 160 of 342

The relative strengths and weaknesses of Xenon Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xenon Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 95% points. The greatest weakness of Xenon Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 49% points.

The company's Economic Capital Ratio, given in the ranking table, is 110%, being 65% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	44,821
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,083
Liabilities, Non-Current	6,104
Other Assets	230
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	1,871
Other Revenues	311
Property and Equipment	1,070
Research and Development	25,573
Selling, General and Administrative Expense	7,313

Output Variable	Value in 1000 USD
Assets	46,121
Liabilities	10,187
Expenses	32,886
Revenues	311
Stockholders Equity	35,934
Net Income	-30,704
Comprehensive Net Income	-30,704
Economic Capital Ratio	110%

